Orion Portfolio Solutions LLC increased its stake in shares of Insulet Co. (NASDAQ:PODD - Free Report) by 86.2% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 7,826 shares of the medical instruments supplier's stock after acquiring an additional 3,623 shares during the quarter. Orion Portfolio Solutions LLC's holdings in Insulet were worth $1,822,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Blue Trust Inc. lifted its holdings in Insulet by 84.1% during the 3rd quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier's stock worth $30,000 after purchasing an additional 58 shares in the last quarter. International Assets Investment Management LLC purchased a new stake in shares of Insulet during the second quarter worth about $32,000. Venturi Wealth Management LLC increased its stake in shares of Insulet by 633.3% during the third quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier's stock valued at $36,000 after buying an additional 133 shares during the period. UMB Bank n.a. lifted its position in shares of Insulet by 81.0% in the 2nd quarter. UMB Bank n.a. now owns 181 shares of the medical instruments supplier's stock worth $37,000 after purchasing an additional 81 shares during the period. Finally, 1620 Investment Advisors Inc. bought a new stake in Insulet during the 2nd quarter valued at approximately $52,000.
Insider Activity at Insulet
In other Insulet news, CAO Lauren Budden sold 915 shares of Insulet stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total transaction of $252,192.30. Following the transaction, the chief accounting officer now directly owns 5,733 shares of the company's stock, valued at $1,580,129.46. The trade was a 13.76 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. 0.47% of the stock is currently owned by company insiders.
Insulet Stock Performance
PODD traded down $2.39 during trading on Friday, hitting $269.34. 571,633 shares of the stock were exchanged, compared to its average volume of 762,207. The stock has a fifty day moving average price of $250.58 and a two-hundred day moving average price of $219.40. Insulet Co. has a 1-year low of $160.19 and a 1-year high of $279.77. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21. The firm has a market capitalization of $18.89 billion, a P/E ratio of 46.53, a PEG ratio of 4.18 and a beta of 1.21.
Analyst Upgrades and Downgrades
PODD has been the subject of a number of recent analyst reports. JPMorgan Chase & Co. boosted their price objective on shares of Insulet from $280.00 to $330.00 and gave the stock an "overweight" rating in a report on Thursday. Citigroup upped their target price on shares of Insulet from $283.00 to $310.00 and gave the company a "buy" rating in a report on Wednesday. Canaccord Genuity Group raised their price objective on Insulet from $269.00 to $304.00 and gave the stock a "buy" rating in a research note on Monday. Sanford C. Bernstein began coverage on shares of Insulet in a research note on Wednesday, November 6th. They set an "outperform" rating and a $300.00 target price on the stock. Finally, BTIG Research upped their price target on Insulet from $260.00 to $270.00 and gave the stock a "buy" rating in a research note on Friday, November 8th. Three equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. Based on data from MarketBeat.com, Insulet presently has an average rating of "Moderate Buy" and a consensus price target of $267.44.
Get Our Latest Stock Report on Insulet
Insulet Profile
(
Free Report)
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.
See Also
Before you consider Insulet, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Insulet wasn't on the list.
While Insulet currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
